Annex 
Conditions or restrictions with regard to the safe and effective use of the medicinal product to be 
implemented by the Member States 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditions or restrictions with regard to the safe and effective use of the medicinal product to be 
implemented by the Member States 
The Member States should ensure that all conditions or restrictions with regard to the safe and 
effective use of the medicinal product described below are implemented: 
The Marketing Authorisation Holder (MAH) shall ensure that, at launch, a letter is sent to all expected 
and actual prescribers of NovoThirteen with an Educational Pack containing the following: 
1. 
2. 
Physician brochure 
Patient brochure 
Both documents are to be used as part of an educational plan aiming to minimise risks of medication 
errors, risk of thromboembolic events due to increased levels of non-proteolytically activated rFXIII in 
connection with incorrect storage, and risk of off-label use for treatment of breakthrough bleeding. 
The MAH should ensure harmonisation between terminology used in the brochures and the product 
information. 
The physician brochure should contain the following key elements and item: 
• 
• 
• 
• 
indication of the product 
the risks of off-label use within FXIII congenital deficiency 
appropriate diagnostic procedures to confirm FXIII A-subunit deficiency 
warning of the difference of both posology and concentration between NovoThirteen and other 
FXIII containing products (The recommended dose of NovoThirteen is 35 IU/kg body weight 
(bw) once monthly, administered as an intravenous bolus injection. The dose volume in 
millilitres should be calculated based on body weight for each patient using the following 
formula: Dose volume in ml = 0.042 x subject bw (kg).) 
correct handling and the risks associated with mishandling 
embolic and thrombotic events including the increased risk of vessel occlusion in patients at risk 
of thrombosis 
what to do in the event of incorrect storage, thrombosis or embolism 
contraindication of hypersensitivity 
warning and precautions regarding anaphylaxis 
the importance of collecting safety data and how to enrol patients in the PASS and other 
registries 
distribution and use of the patient brochure and the need to ensure that the patient has read and 
understood the brochure 
Summary of Product Characteristics 
• 
• 
• 
• 
• 
• 
• 
• 
The patient brochure, to be distributed to patients by the prescribers, should contain the following key 
elements and item: 
• 
• 
• 
• 
• 
• 
• 
indication  of the product 
the risks of off-label use within FXIII congenital deficiency 
how to safely store, handle, reconstitute and administer the product 
the risks associated with incorrect storage and mishandling 
how to recognise the potential side effects (thrombosis and embolism)  
what to do in the event of incorrect storage, thrombosis or embolism 
Package Leaflet  
The Marketing Authorisation Holder must implement this educational plan nationally, prior to 
marketing. The final content, format and distribution modalities of both documents should be agreed 
with the national competent authority in each Member State. 
2 
 
 
 
 
 
 
 
